$2.22 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 91 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 35.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AVXS | Sell | AVEXIS INC | $149,679,000 | -21.1% | 1,547,386 | -33.0% | 6.74% | -33.3% |
| HZNP | Sell | HORIZON PHARMA PLC | $87,708,000 | -17.9% | 6,917,070 | -23.1% | 3.95% | -30.6% |
| NXTM | Sell | NXSTAGE MEDICAL INC | $43,588,000 | -54.6% | 1,579,285 | -58.8% | 1.96% | -61.7% |
| BOLD | Sell | AUDENTES THERAPEUTICS INC | $42,727,000 | +29.2% | 1,525,410 | -11.8% | 1.92% | +9.1% |
| AERI | Sell | AERIE PHARMACEUTICALS INC | $30,749,000 | -39.1% | 632,686 | -34.2% | 1.38% | -48.6% |
| DBVT | Sell | DBV TECHNOLOGIES S Asponsored adr | $27,836,000 | +17.2% | 655,897 | -1.4% | 1.25% | -1.0% |
| LCI | Sell | LANNET INC | $26,813,000 | -13.8% | 1,453,259 | -4.6% | 1.21% | -27.1% |
| SELB | Sell | SELECTA BIOSCIENCES INC | $17,367,000 | -17.5% | 951,629 | -10.2% | 0.78% | -30.4% |
| AACH | Sell | AAC HLDGS INC | $17,211,000 | +25.7% | 1,733,276 | -12.3% | 0.78% | +6.2% |
| PTLA | Sell | PORTOLA PHARMACEUTICALS INC | $16,130,000 | -31.5% | 298,545 | -28.7% | 0.73% | -42.1% |
| EHTH | Sell | EHEALTH INC | $16,078,000 | +23.9% | 672,994 | -2.5% | 0.72% | +4.6% |
| LOXO | Sell | LOXO ONCOLOGY INC | $15,568,000 | -22.7% | 169,000 | -32.7% | 0.70% | -34.7% |
| AAAP | Sell | ADVANCED ACCELERATOR APPLICsponsored ads | $14,741,000 | -3.9% | 218,000 | -44.5% | 0.66% | -18.8% |
| GLPG | Sell | GALAPAGOS NVspon adr | $13,228,000 | -7.8% | 130,000 | -30.7% | 0.60% | -22.1% |
| WVE | Sell | WAVE LIFE SCIENCES LTD | $12,615,000 | -9.2% | 580,000 | -22.3% | 0.57% | -23.3% |
| XNCR | Sell | XENCOR INC | $11,964,000 | +0.8% | 522,000 | -7.2% | 0.54% | -14.8% |
| CNC | Sell | CENTENE CORP DEL | $9,871,000 | +3.8% | 102,000 | -14.3% | 0.44% | -12.2% |
| SGMO | Sell | SANGAMO THERAPEUTICS INC | $9,795,000 | +1.7% | 653,000 | -40.3% | 0.44% | -14.2% |
| AXGN | Sell | AXOGEN INC | $6,665,000 | -41.0% | 344,428 | -48.9% | 0.30% | -50.2% |
| BHVN | Sell | BIOHAVEN PHARMACTL HLDG CO L | $6,168,000 | +13.8% | 165,000 | -23.9% | 0.28% | -3.8% |
| STDY | Sell | STEADYMED LTD | $4,753,000 | -47.7% | 1,418,787 | -1.6% | 0.21% | -55.9% |
| SRRA | Sell | SIERRA ONCOLOGY INC | $4,340,000 | +6.1% | 2,800,000 | -19.9% | 0.20% | -10.6% |
| BIOS | Sell | BIOSCRIP INC | $3,045,000 | -15.5% | 1,107,166 | -16.6% | 0.14% | -28.6% |
| AKTX | Sell | AKARI THERAPEUTICS PLCsponsored adr | $2,662,000 | -29.4% | 433,551 | -47.0% | 0.12% | -40.3% |
| PTI | Exit | PROTEOSTASIS THERAPEUTICS IN | $0 | – | -17,251 | -100.0% | -0.00% | – |
| Exit | ESSA PHARMA INC | $0 | – | -1,416,230 | -100.0% | -0.04% | – | |
| BCRX | Exit | BIOCRYST PHARMACEUTICALScall | $0 | – | -500,000 | -100.0% | -0.15% | – |
| KMPH | Exit | KEMPHARM INC | $0 | – | -704,612 | -100.0% | -0.15% | – |
| JNCE | Exit | JOUNCE THERAPEUTICS INC | $0 | – | -247,872 | -100.0% | -0.19% | – |
| MNKD | Exit | MANNKIND CORP | $0 | – | -2,702,403 | -100.0% | -0.20% | – |
| NVLS | Exit | NIVALIS THERAPEUTICS INC | $0 | – | -3,732,412 | -100.0% | -0.48% | – |
| PBYI | Exit | PUMA BIOTECHNOLOGY INCput | $0 | – | -104,000 | -100.0% | -0.48% | – |
| ANTM | Exit | ANTHEM INC | $0 | – | -75,182 | -100.0% | -0.75% | – |
| AET | Exit | AETNA INC NEW | $0 | – | -130,000 | -100.0% | -1.05% | – |
| NVRO | Exit | NEVRO CORP | $0 | – | -376,308 | -100.0% | -1.49% | – |
| GILD | Exit | GILEAD SCIENCES INCcall | $0 | – | -750,000 | -100.0% | -2.83% | – |
| GILD | Exit | GILEAD SCIENCES INC | $0 | – | -938,515 | -100.0% | -3.54% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.